

Robert Dufour

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3441338/publications.pdf>

Version: 2024-02-01

21
papers

1,482
citations

566801

15
h-index

752256

20
g-index

21
all docs

21
docs citations

21
times ranked

2417
citing authors

#	ARTICLE	IF	CITATIONS
1	2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology, 2013, 29, 151-167.	0.8	680
2	Myotoxicity of statins: Mechanism of action. , 2017, 175, 1-16.		106
3	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2014, 30, 1471-1481.	0.8	93
4	Polygenic risk score predicts prevalence of cardiovascular disease in patients with familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 725-732.e5.	0.6	90
5	PCSK9 R46L, Lower LDL, and Cardiovascular Disease Risk in Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2700-2705.	1.1	67
6	The Montreal-FH-SCORE: A new score to predict cardiovascular events in familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 80-86.	0.6	63
7	Simplified Canadian Definition for Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2018, 34, 1210-1214.	0.8	62
8	The effect of insulin on circulating PCSK9 in postmenopausal obese women. Clinical Biochemistry, 2014, 47, 1033-1039.	0.8	47
9	Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk. Journal of Clinical Lipidology, 2015, 9, 786-793.e1.	0.6	47
10	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. Clinical Chemistry, 2018, 64, 355-362.	1.5	47
11	Cardiovascular disease in familial hypercholesterolemia: Validation and refinement of the Montreal-FH-SCORE. Journal of Clinical Lipidology, 2017, 11, 1161-1167.e3.	0.6	42
12	ABO blood group is a cardiovascular risk factor in patients with familial hypercholesterolemia. Journal of Clinical Lipidology, 2018, 12, 383-389.e1.	0.6	25
13	Scavenger Receptor LOX1 Genotype Predicts Coronary Artery Disease in Patients With Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2017, 33, 1312-1318.	0.8	18
14	ApoB-lipoproteins and dysfunctional white adipose tissue: Relation to risk factors for type 2 diabetes in humans. Journal of Clinical Lipidology, 2017, 11, 34-45.e2.	0.6	18
15	Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry. Atherosclerosis, 2018, 277, 419-424.	0.4	18
16	The 9p21.3 locus and cardiovascular risk in familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 406-412.	0.6	17
17	Association Between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and the Presence of Metabolic Syndrome in a Predominantly Rural-Based Sub-Saharan African Population. Metabolic Syndrome and Related Disorders, 2017, 15, 423-429.	0.5	13
18	A tale of 2 cousins: An atypical and a typical case of abetalipoproteinemia. Journal of Clinical Lipidology, 2016, 10, 1030-1034.	0.6	11

#	ARTICLE	IF	CITATIONS
19	Effects of rs3846662 Variants on HMGR mRNA and Protein Levels and on Markers of Alzheimer's Disease Pathology. <i>Journal of Molecular Neuroscience</i> , 2016, 58, 109-119.	1.1	10
20	PHACTR1 genotype predicts coronary artery disease in patients with familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2018, 12, 966-971.	0.6	5
21	Predicting proprotein convertase subtilisin kexin type-9 loss of function mutations using plasma PCSK9 concentration. <i>Journal of Clinical Lipidology</i> , 2017, 11, 55-60.	0.6	3